From SARS to MERS, Thrusting Coronaviruses into the Spotlight
Tóm tắt
Từ khóa
Tài liệu tham khảo
Yin, 2018, MERS, SARS and other coronaviruses as causes of pneumonia, Respirology, 23, 130, 10.1111/resp.13196
Drosten, 2003, Identification of a novel coronavirus in patients with severe acute respiratory syndrome, N. Engl. J. Med., 348, 1967, 10.1056/NEJMoa030747
Ksiazek, 2003, A novel coronavirus associated with severe acute respiratory syndrome, N. Engl. J. Med., 348, 1953, 10.1056/NEJMoa030781
Rota, 2003, Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome, Science, 300, 1394, 10.1126/science.1085952
Zhong, 2003, Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February, 2003, Lancet, 362, 1353, 10.1016/S0140-6736(03)14630-2
Lee, 2003, A major outbreak of severe acute respiratory syndrome in Hong Kong, N. Engl. J. Med., 348, 1986, 10.1056/NEJMoa030685
Ge, 2013, Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor, Nature, 503, 535, 10.1038/nature12711
Menachery, 2015, A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence, Nat. Med., 21, 1508, 10.1038/nm.3985
Zaki, 2012, Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia, N. Engl. J. Med., 367, 1814, 10.1056/NEJMoa1211721
Falzarano, 2016, SARS and MERS: Recent insights into emerging coronaviruses, Nat. Rev. Microbiol., 14, 523, 10.1038/nrmicro.2016.81
World Health Organization (2018, October 08). WHO Guidelines for the Global Surveillance of Severe Acute Respiratory Syndrome (SARS). Available online: http://www.who.int/mediacentre/factsheets/mers-cov/en/.
Guan, 2003, Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China, Science, 302, 276, 10.1126/science.1087139
Azhar, 2014, Evidence for camel-to-human transmission of MERS coronavirus, N. Engl. J. Med., 370, 2499, 10.1056/NEJMoa1401505
Cui, J., Li, F., and Shi, Z. (2018). Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol.
Alshukairi, 2018, High Prevalence of MERS-CoV Infection in Camel Workers in Saudi Arabia, mBio, 9, e01985-18, 10.1128/mBio.01985-18
Assiri, 2013, Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: A descriptive study, Lancet Infect. Dis., 13, 752, 10.1016/S1473-3099(13)70204-4
Arabi, 2014, Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection, Ann. Intern. Med., 160, 389, 10.7326/M13-2486
Payne, 2014, Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: A serologic, epidemiologic, and clinical description, Clin. Infect. Dis., 59, 1225, 10.1093/cid/ciu359
Al, 2016, Response to Emergence of Middle East Respiratory Syndrome Coronavirus, Abu Dhabi, United Arab Emirates, 2013–2014, Emerg. Infect. Dis., 22, 1162, 10.3201/eid2207.160040
Assiri, 2013, Hospital outbreak of Middle East respiratory syndrome coronavirus, N. Engl. J. Med., 369, 407, 10.1056/NEJMoa1306742
Drosten, 2015, An observational, laboratory-based study of outbreaks of middle East respiratory syndrome coronavirus in Jeddah and Riyadh, kingdom of Saudi Arabia, 2014, Clin. Infect. Dis., 60, 369, 10.1093/cid/ciu812
Park, 2015, Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015, Eurosurveillance, 20, 21169, 10.2807/1560-7917.ES2015.20.25.21169
Skowronski, 2005, Severe acute respiratory syndrome (SARS): A year in review, Annu. Rev. Med., 56, 357, 10.1146/annurev.med.56.091103.134135
Fehr, 2015, Coronaviruses: An overview of their replication and pathogenesis, Methods Mol. Biol., 1282, 1, 10.1007/978-1-4939-2438-7_1
Wang, 2018, Current understanding of middle east respiratory syndrome coronavirus infection in human and animal models, J. Thorac. Dis., 10, S2260, 10.21037/jtd.2018.03.80
Du, 2017, MERS-CoV spike protein: A key target for antivirals, Expert Opin. Ther. Targets, 21, 131, 10.1080/14728222.2017.1271415
Du, 2009, The spike protein of SARS-CoV—A target for vaccine and therapeutic development, Nat. Rev. Microbiol., 7, 226, 10.1038/nrmicro2090
Jeffers, 2004, CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus, Proc. Natl. Acad. Sci. USA, 101, 15748, 10.1073/pnas.0403812101
Liu, 2011, Epithelial Cells Lining Salivary Gland Ducts Are Early Target Cells of Severe Acute Respiratory Syndrome Coronavirus Infection in the Upper Respiratory Tracts of Rhesus Macaques, J. Virol., 85, 4025, 10.1128/JVI.02292-10
Kuba, 2005, A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury, Nat. Med., 11, 875, 10.1038/nm1267
Qinfen, 2004, The life cycle of SARS coronavirus in Vero E6 cells, J. Med. Virol., 73, 332, 10.1002/jmv.20095
Guo, 2008, Pathogenetic mechanisms of severe acute respiratory syndrome, Virus Res., 133, 4, 10.1016/j.virusres.2007.01.022
Gu, 2007, Pathology and pathogenesis of severe acute respiratory syndrome, Am. J. Pathol., 170, 1136, 10.2353/ajpath.2007.061088
Ding, 2004, Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: Implications for pathogenesis and virus transmission pathways, J. Pathol., 203, 622, 10.1002/path.1560
Meyerholz, 2016, Dipeptidyl Peptidase 4 Distribution in the Human Respiratory Tract: Implications for the Middle East Respiratory Syndrome, Am. J. Pathol., 186, 78, 10.1016/j.ajpath.2015.09.014
Widagdo, 2016, Differential Expression of the Middle East Respiratory Syndrome Coronavirus Receptor in the Upper Respiratory Tracts of Humans and Dromedary Camels, J. Virol., 90, 4838, 10.1128/JVI.02994-15
Oboho, 2015, 2014 MERS-CoV outbreak in Jeddah—A link to health care facilities, N. Engl. J. Med., 372, 846, 10.1056/NEJMoa1408636
Chu, 2005, Acute renal impairment in coronavirus-associated severe acute respiratory syndrome, Kidney Int., 67, 698, 10.1111/j.1523-1755.2005.67130.x
Saad, 2014, Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: A single-center experience in Saudi Arabia, Int. J. Infect. Dis., 29, 301, 10.1016/j.ijid.2014.09.003
Alagaili, 2014, Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia, mBio, 5, e814
Lambeir, 2003, Dipeptidyl-peptidase IV from bench to bedside: An update on structural properties, functions, and clinical aspects of the enzyme DPP IV, Crit. Rev. Clin. Lab. Sci., 40, 209, 10.1080/713609354
Chu, 2014, Productive replication of Middle East respiratory syndrome coronavirus in monocyte-derived dendritic cells modulates innate immune response, Virology, 454–455, 197, 10.1016/j.virol.2014.02.018
Zhou, 2014, Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: Implications for pathogenesis, J. Infect. Dis., 209, 1331, 10.1093/infdis/jit504
Chu, 2016, Middle East Respiratory Syndrome Coronavirus Efficiently Infects Human Primary T Lymphocytes and Activates the Extrinsic and Intrinsic Apoptosis Pathways, J. Infect. Dis., 213, 904, 10.1093/infdis/jiv380
Yeung, 2016, MERS coronavirus induces apoptosis in kidney and lung by upregulating Smad7 and FGF2, Nat. Microbiol., 1, 16004, 10.1038/nmicrobiol.2016.4
Liu, 2017, Protective T Cell Res.ponses Featured by Concordant Recognition of Middle East Respiratory Syndrome Coronavirus-Derived CD8+ T Cell Epitopes and Host MHC, J. Immunol., 198, 873, 10.4049/jimmunol.1601542
Chan, 2013, Tropism of and innate immune responses to the novel human betacoronavirus lineage C virus in human ex vivo respiratory organ cultures, J. Virol., 87, 6604, 10.1128/JVI.00009-13
Lau, 2013, Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: Implications for pathogenesis and treatment, J. Gen. Virol., 94, 2679, 10.1099/vir.0.055533-0
Marra, 2003, The Genome sequence of the SARS-associated coronavirus, Science, 300, 1399, 10.1126/science.1085953
Qu, 2005, Identification of two critical amino acid residues of the severe acute respiratory syndrome coronavirus spike protein for its variation in zoonotic tropism transition via a double substitution strategy, J. Biol. Chem., 280, 29588, 10.1074/jbc.M500662200
Li, 2005, Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2, EMBO J., 24, 1634, 10.1038/sj.emboj.7600640
Li, 2005, Structure of SARS coronavirus spike receptor-binding domain complexed with receptor, Science, 309, 1864, 10.1126/science.1116480
Li, 2015, Receptor recognition mechanisms of coronaviruses: A decade of structural studies, J. Virol., 89, 1954, 10.1128/JVI.02615-14
Lu, 2013, Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26, Nature, 500, 227, 10.1038/nature12328
Gao, 2013, Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus, J. Virol., 87, 13134, 10.1128/JVI.02433-13
Wang, 2013, Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4, Cell Res., 23, 986, 10.1038/cr.2013.92
Zhang, 2014, Current advancements and potential strategies in the development of MERS-CoV vaccines, Expert Rev. Vaccines, 13, 761, 10.1586/14760584.2014.912134
Du, 2013, Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development, J. Virol., 87, 9939, 10.1128/JVI.01048-13
Raj, 2013, Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC, Nature, 495, 251, 10.1038/nature12005
Li, 2003, Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus, Nature, 426, 450, 10.1038/nature02145
Chen, 2013, Crystal structure of the receptor-binding domain from newly emerged Middle East respiratory syndrome coronavirus, J. Virol., 87, 10777, 10.1128/JVI.01756-13
Lu, 2014, Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor, Nat. Commun., 5, 3067, 10.1038/ncomms4067
Zheng, 2006, Core structure of S2 from the human coronavirus NL63 spike glycoprotein, Biochemistry, 45, 15205, 10.1021/bi061686w
Xu, 2004, Crystal structure of severe acute respiratory syndrome coronavirus spike protein fusion core, J. Biol. Chem., 279, 49414, 10.1074/jbc.M408782200
Xu, 2004, Structural basis for coronavirus-mediated membrane fusion. Crystal structure of mouse hepatitis virus spike protein fusion core, J. Biol. Chem., 279, 30514, 10.1074/jbc.M403760200
Hofmann, 2004, S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients, J. Virol., 78, 6134, 10.1128/JVI.78.12.6134-6142.2004
Li, 2006, Conformational states of the severe acute respiratory syndrome coronavirus spike protein ectodomain, J. Virol., 80, 6794, 10.1128/JVI.02744-05
Wong, 2004, A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2, J. Biol. Chem., 279, 3197, 10.1074/jbc.C300520200
Xiao, 2003, The SARS-CoV S glycoprotein: Expression and functional characterization, Biochem. Biophys. Res. Commun., 312, 1159, 10.1016/j.bbrc.2003.11.054
Zhang, 2005, A molecular docking model of SARS-CoV S1 protein in complex with its receptor, human ACE2, Comput. Biol. Chem., 29, 254, 10.1016/j.compbiolchem.2005.04.008
He, 2006, A single amino acid substitution (R441A) in the receptor-binding domain of SARS coronavirus spike protein disrupts the antigenic structure and binding activity, Biochem. Biophys. Res. Commun., 344, 106, 10.1016/j.bbrc.2006.03.139
Sainz, 2005, Identification and characterization of the putative fusion peptide of the severe acute respiratory syndrome-associated coronavirus spike protein, J. Virol., 79, 7195, 10.1128/JVI.79.11.7195-7206.2005
Yang, 2004, pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN, J. Virol., 78, 5642, 10.1128/JVI.78.11.5642-5650.2004
Han, 2007, Specific asparagine-linked glycosylation sites are critical for DC-SIGN- and L-SIGN-mediated severe acute respiratory syndrome coronavirus entry, J. Virol., 81, 12029, 10.1128/JVI.00315-07
Graham, 2013, A decade after SARS: Strategies for controlling emerging coronaviruses, Nat. Rev. Microbiol., 11, 836, 10.1038/nrmicro3143
Keng, 2005, Amino acids 1055 to 1192 in the S2 region of severe acute respiratory syndrome coronavirus S protein induce neutralizing antibodies: Implications for the development of vaccines and antiviral agents, J. Virol., 79, 3289, 10.1128/JVI.79.6.3289-3296.2005
Zhou, 2004, An exposed domain in the severe acute respiratory syndrome coronavirus spike protein induces neutralizing antibodies, J. Virol., 78, 7217, 10.1128/JVI.78.13.7217-7226.2004
Bukreyev, 2004, Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS, Lancet, 363, 2122, 10.1016/S0140-6736(04)16501-X
Yang, 2004, A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice, Nature, 428, 561, 10.1038/nature02463
Kam, 2007, Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro, Vaccine, 25, 729, 10.1016/j.vaccine.2006.08.011
Czub, 2005, Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets, Vaccine, 23, 2273, 10.1016/j.vaccine.2005.01.033
Weingartl, 2004, Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets, J. Virol., 78, 12672, 10.1128/JVI.78.22.12672-12676.2004
Tai, 2017, Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants, J. Virol., 91, e01651-16, 10.1128/JVI.01651-16
Wang, 2015, Evaluation of candidate vaccine approaches for MERS-CoV, Nat. Commun., 6, 7712, 10.1038/ncomms8712
Gilbert, 2017, Rapid development of vaccines against emerging pathogens: The replication-deficient simian adenovirus platform technology, Vaccine, 35, 4461, 10.1016/j.vaccine.2017.04.085
Kim, 2014, Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice, Vaccine, 32, 5975, 10.1016/j.vaccine.2014.08.058
Chi, 2017, DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice, Vaccine, 35, 2069, 10.1016/j.vaccine.2017.02.063
Abbas, 2017, Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein, Sci. Rep., 7, 44875, 10.1038/srep44875
Modjarrad, 2016, MERS-CoV vaccine candidates in development: The current landscape, Vaccine, 34, 2982, 10.1016/j.vaccine.2016.03.104
Zhao, 2016, Airway Memory CD4+ T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses, Immunity, 44, 1379, 10.1016/j.immuni.2016.05.006
Lin, 2007, Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine, Antivir. Ther., 12, 1107, 10.1177/135965350701200702
Deng, 2018, Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus, Emerg. Microbes Infect., 7, 60, 10.1038/s41426-018-0056-7
See, 2006, Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus, J. Gen. Virol., 87, 641, 10.1099/vir.0.81579-0
Enjuanes, 2008, Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease, Virus Res., 133, 45, 10.1016/j.virusres.2007.01.021
Bolles, 2011, A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge, J. Virol., 85, 12201, 10.1128/JVI.06048-11
Ishioka, 2011, Effects of respiratory syncytial virus infection and major basic protein derived from eosinophils in pulmonary alveolar epithelial cells (A549), Cell Biol. Int., 35, 467, 10.1042/CBI20100255
Fett, 2013, Complete protection against severe acute respiratory syndrome coronavirus-mediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein, J. Virol., 87, 6551, 10.1128/JVI.00087-13
Graham, 2012, A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease, Nat. Med., 18, 1820, 10.1038/nm.2972
Almazan, 2013, Engineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate, mBio, 4, e613, 10.1128/mBio.00650-13
Vignuzzi, 2008, Engineering attenuated virus vaccines by controlling replication fidelity, Nat. Med., 14, 154, 10.1038/nm1726
Roberts, 2005, Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters, J. Virol., 79, 503, 10.1128/JVI.79.1.503-511.2005
Deming, D., Sheahan, T., Heise, M., Yount, B., Davis, N., Sims, A., Suthar, M., Harkema, J., Whitmore, A., and Pickles, R. (2006). Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Med., 3.
Chen, 2005, Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region, J. Virol., 79, 2678, 10.1128/JVI.79.5.2678-2688.2005
Lan, 2015, Recombinant Receptor Binding Domain Protein Induces Partial Protective Immunity in Rhesus Macaques Against Middle East Respiratory Syndrome Coronavirus Challenge, EBioMedicine, 2, 1438, 10.1016/j.ebiom.2015.08.031
Jiaming, 2017, The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection, Vaccine, 35, 10, 10.1016/j.vaccine.2016.11.064
Bisht, 2005, Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein, Virology, 334, 160, 10.1016/j.virol.2005.01.042
Woo, 2005, SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus, Vaccine, 23, 4959, 10.1016/j.vaccine.2005.05.023
Shi, 2006, The expression of membrane protein augments the specific responses induced by SARS-CoV nucleocapsid DNA immunization, Mol. Immunol., 43, 1791, 10.1016/j.molimm.2005.11.005
Gupta, 2006, SARS coronavirus nucleocapsid immunodominant T-cell epitope cluster is common to both exogenous recombinant and endogenous DNA-encoded immunogens, Virology, 347, 127, 10.1016/j.virol.2005.11.042
Zhuang, 2009, Procyanidins and butanol extract of Cinnamomi Cortex inhibit SARS-CoV infection, Antivir. Res., 82, 73, 10.1016/j.antiviral.2009.02.001
Hu, 2005, Screening and identification of linear B-cell epitopes and entry-blocking peptide of severe acute respiratory syndrome (SARS)-associated coronavirus using synthetic overlapping peptide library, J. Comb. Chem., 7, 648, 10.1021/cc0500607
Zheng, 2005, Synthetic peptides outside the spike protein heptad repeat regions as potent inhibitors of SARS-associated coronavirus, Antivir. Ther., 10, 393, 10.1177/135965350501000301
Bosch, 2004, Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides, Proc. Natl. Acad. Sci. USA, 101, 8455, 10.1073/pnas.0400576101
Yuan, 2004, Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein, Biochem. Biophys. Res. Commun., 319, 746, 10.1016/j.bbrc.2004.05.046
McRoy, 2008, Amino acid substitutions in the S2 subunit of mouse hepatitis virus variant V51 encode determinants of host range expansion, J. Virol., 82, 1414, 10.1128/JVI.01674-07
He, 2006, Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: Implication for vaccine design, J. Virol., 80, 5757, 10.1128/JVI.00083-06
He, 2006, Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein, J. Immunol., 176, 6085, 10.4049/jimmunol.176.10.6085
He, 2005, Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: Importance for designing SARS vaccines, Virology, 334, 74, 10.1016/j.virol.2005.01.034
Lai, 2005, Characterization of neutralizing monoclonal antibodies recognizing a 15-residues epitope on the spike protein HR2 region of severe acute respiratory syndrome coronavirus (SARS-CoV), J. Biomed. Sci., 12, 711, 10.1007/s11373-005-9004-3
Nie, 2004, Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection, J. Infect. Dis., 190, 1119, 10.1086/423286
Traggiai, 2004, An efficient method to make human monoclonal antibodies from memory B cells: Potent neutralization of SARS coronavirus, Nat. Med., 10, 871, 10.1038/nm1080
Rockx, 2008, Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge, J. Virol., 82, 3220, 10.1128/JVI.02377-07
Zhu, 2007, Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies, Proc. Natl. Acad. Sci. USA, 104, 12123, 10.1073/pnas.0701000104
Coughlin, 2007, Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse, Virology, 361, 93, 10.1016/j.virol.2006.09.029
Cox, 2005, Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus, J. Virol., 79, 1635, 10.1128/JVI.79.3.1635-1644.2005
Sui, 2004, Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association, Proc. Natl. Acad. Sci. USA, 101, 2536, 10.1073/pnas.0307140101
Liu, 2004, Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: Implications for virus fusogenic mechanism and identification of fusion inhibitors, Lancet, 363, 938, 10.1016/S0140-6736(04)15788-7
Corti, 2015, Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus, Proc. Natl. Acad. Sci. USA, 112, 10473, 10.1073/pnas.1510199112
Li, 2015, A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein, Cell Res., 25, 1237, 10.1038/cr.2015.113
Du, 2014, A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein, J. Virol., 88, 7045, 10.1128/JVI.00433-14
Raj, 2014, Adenosine deaminase acts as a natural antagonist for dipeptidyl peptidase 4-mediated entry of the Middle East respiratory syndrome coronavirus, J. Virol., 88, 1834, 10.1128/JVI.02935-13
Zhou, 2016, Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), J. Biol. Chem., 291, 9218, 10.1074/jbc.M116.716100
Gierer, 2013, The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies, J. Virol., 87, 5502, 10.1128/JVI.00128-13
Shirato, 2013, Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2, J. Virol., 87, 12552, 10.1128/JVI.01890-13
Zhou, 2015, Protease inhibitors targeting coronavirus and filovirus entry, Antivir. Res., 116, 76, 10.1016/j.antiviral.2015.01.011
Momattin, 2013, Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV)–possible lessons from a systematic review of SARS-CoV therapy, Int. J. Infect. Dis., 17, e792, 10.1016/j.ijid.2013.07.002
Hart, 2014, Interferon-beta and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays, J. Gen. Virol., 95, 571, 10.1099/vir.0.061911-0
ter Meulen, J., van den Brink, E.N., Poon, L.L., Marissen, W.E., Leung, C.S., Cox, F., Cheung, C.Y., Bakker, A.Q., Bogaards, J.A., and van Deventer, E. (2006). Human monoclonal antibody combination against SARS coronavirus: Synergy and coverage of escape mutants. PLoS Med., 3.
Zhang, 2005, A serological survey on neutralizing antibody titer of SARS convalescent sera, J. Med. Virol., 77, 147, 10.1002/jmv.20431
Ishida, 2011, Fully Human Monoclonal Antibody Directed to Proteolytic Cleavage Site in Severe Acute Respiratory Syndrome (SARS) Coronavirus S Protein Neutralizes the Virus in a Rhesus Macaque SARS Model, J. Infect. Dis., 203, 1574, 10.1093/infdis/jir084
Wang, 2016, Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates, ACS Infect. Dis., 2, 361, 10.1021/acsinfecdis.6b00006
Chen, 2017, Human Neutralizing Monoclonal Antibody Inhibition of Middle East Respiratory Syndrome Coronavirus Replication in the Common Marmoset, J. Infect. Dis., 215, 1807, 10.1093/infdis/jix209
Stockman, L.J., Bellamy, R., Garner, P., and Low, D. (2006). SARS: Systematic Review of Treatment Effects. PLoS Med., 3.
Chan, 2006, SARS: Clinical presentation, transmission, pathogenesis and treatment options, Clin. Sci., 110, 193, 10.1042/CS20050188
Chan, 2015, Treatment with Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset, J. Infect. Dis., 212, 1904, 10.1093/infdis/jiv392
Subbarao, 2004, Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice, J. Virol., 78, 3572, 10.1128/JVI.78.7.3572-3577.2004
Wentworth, 2004, Mice susceptible to SARS coronavirus, Emerg. Infect. Dis., 10, 1293, 10.3201/eid1007.031119
Glass, 2004, Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice, J. Immunol., 173, 4030, 10.4049/jimmunol.173.6.4030
Yang, 2007, Mice transgenic for human angiotensin-converting enzyme 2 provide a model for SARS coronavirus infection, Comp. Med., 57, 450
Roberts, 2005, Aged BALB/c mice as a model for increased severity of severe acute respiratory syndrome in elderly humans, J. Virol., 79, 5833, 10.1128/JVI.79.9.5833-5838.2005
Hogan, 2004, Resolution of primary severe acute respiratory syndrome-associated coronavirus infection requires Stat1, J. Virol., 78, 11416, 10.1128/JVI.78.20.11416-11421.2004
Frieman, 2012, Molecular determinants of severe acute respiratory syndrome coronavirus pathogenesis and virulence in young and aged mouse models of human disease, J. Virol., 86, 884, 10.1128/JVI.05957-11
Zhao, 2011, Age-related increases in PGD(2) expression impair respiratory DC migration, resulting in diminished T cell responses upon respiratory virus infection in mice, J. Clin. Investig., 121, 4921, 10.1172/JCI59777
Zhao, 2010, T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice, J. Virol., 84, 9318, 10.1128/JVI.01049-10
Zhao, J., Zhao, J., Van Rooijen, N., and Perlman, S. (2009). Evasion by stealth: Inefficient immune activation underlies poor T cell response and severe disease in SARS-CoV-infected mice. PLoS Pathog., 5.
Sheahan, T., Morrison, T.E., Funkhouser, W., Uematsu, S., Akira, S., Baric, R.S., and Heise, M.T. (2008). MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV. PLoS Pathog., 4.
Li, 2008, T cell responses to whole SARS coronavirus in humans, J. Immunol., 181, 5490, 10.4049/jimmunol.181.8.5490
Chen, 2004, Antibody response and viraemia during the course of severe acute respiratory syndrome (SARS)-associated coronavirus infection, J. Med. Microbiol., 53, 435, 10.1099/jmm.0.45561-0
Spruth, 2006, A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses, Vaccine, 24, 652, 10.1016/j.vaccine.2005.08.055
Greenough, 2005, Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice, J. Infect. Dis., 191, 507, 10.1086/427242
Kapadia, 2005, Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine, Virology, 340, 174, 10.1016/j.virol.2005.06.016
Stadler, 2005, SARS vaccine protective in mice, Emerg. Infect. Dis., 11, 1312, 10.3201/eid1108.041003
Bisht, 2004, Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice, Proc. Natl. Acad. Sci. USA, 101, 6641, 10.1073/pnas.0401939101
Schaecher, 2008, An immunosuppressed Syrian golden hamster model for SARS-CoV infection, Virology, 380, 312, 10.1016/j.virol.2008.07.026
Luo, 2007, Protection from infection with severe acute respiratory syndrome coronavirus in a Chinese hamster model by equine neutralizing F(ab’)2, Viral Immunol., 20, 495, 10.1089/vim.2007.0038
Subbarao, 2006, Is there an ideal animal model for SARS?, Trends Microbiol., 14, 299, 10.1016/j.tim.2006.05.007
Roberts, 2006, Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters, J. Infect. Dis., 193, 685, 10.1086/500143
Martina, 2003, Virology: SARS virus infection of cats and ferrets, Nature, 425, 915, 10.1038/425915a
Haagmans, 2008, Pathology of experimental SARS coronavirus infection in cats and ferrets, Vet. Pathol., 45, 551, 10.1354/vp.45-4-551
Darnell, 2007, Severe acute respiratory syndrome coronavirus infection in vaccinated ferrets, J. Infect. Dis., 196, 1329, 10.1086/522431
Bakker, 2004, Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets, Lancet, 363, 2139, 10.1016/S0140-6736(04)16506-9
See, 2008, Severe acute respiratory syndrome vaccine efficacy in ferrets: Whole killed virus and adenovirus-vectored vaccines, J. Gen. Virol., 89, 2136, 10.1099/vir.0.2008/001891-0
Qin, 2005, An animal model of SARS produced by infection of Macaca mulatta with SARS coronavirus, J. Pathol., 206, 251, 10.1002/path.1769
McAuliffe, 2004, Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys, Virology, 330, 8, 10.1016/j.virol.2004.09.030
Rowe, 2004, Macaque model for severe acute respiratory syndrome, J. Virol., 78, 11401, 10.1128/JVI.78.20.11401-11404.2004
Li, 2005, Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque, Nat. Med., 11, 944, 10.1038/nm1280
Liu, 2016, Spatiotemporal interplay of severe acute respiratory syndrome coronavirus and respiratory mucosal cells drives viral dissemination in rhesus macaques, Mucosal Immunol., 9, 1089, 10.1038/mi.2015.127
Fouchier, 2003, Aetiology: Koch’s postulates fulfilled for SARS virus, Nature, 423, 240, 10.1038/423240a
Kuiken, 2003, Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome, Lancet, 362, 263, 10.1016/S0140-6736(03)13967-0
Greenough, 2005, Pneumonitis and multi-organ system disease in common marmosets (Callithrix jacchus) infected with the severe acute respiratory syndrome-associated coronavirus, Am. J. Pathol., 167, 455, 10.1016/S0002-9440(10)62989-6
Lawler, J.V., Endy, T.P., Hensley, L.E., Garrison, A., Fritz, E.A., Lesar, M., Baric, R.S., Kulesh, D.A., Norwood, D.A., and Wasieloski, L.P. (2006). Cynomolgus macaque as an animal model for severe acute respiratory syndrome. PLoS Med., 3.
Chen, 2008, Rhesus angiotensin converting enzyme 2 supports entry of severe acute respiratory syndrome coronavirus in Chinese macaques, Virology, 381, 89, 10.1016/j.virol.2008.08.016
Cockrell, 2014, Mouse dipeptidyl peptidase 4 is not a functional receptor for Middle East respiratory syndrome coronavirus infection, J. Virol., 88, 5195, 10.1128/JVI.03764-13
Coleman, 2014, Wild-type and innate immune-deficient mice are not susceptible to the Middle East respiratory syndrome coronavirus, J. Gen. Virol., 95, 408, 10.1099/vir.0.060640-0
Feldmann, 2017, Domestic Pig Unlikely Reservoir for MERS-CoV, Emerg. Infect. Dis., 23, 985, 10.3201/eid2306.170096
Peck, 2017, Permissivity of Dipeptidyl Peptidase 4 Orthologs to Middle East Respiratory Syndrome Coronavirus Is Governed by Glycosylation and Other Complex Determinants, J. Virol., 91, e00534-17, 10.1128/JVI.00534-17
Haagmans, 2015, Asymptomatic Middle East respiratory syndrome coronavirus infection in rabbits, J. Virol., 89, 6131, 10.1128/JVI.00661-15
de Wit, E., Prescott, J., Baseler, L., Bushmaker, T., Thomas, T., Lackemeyer, M.G., Martellaro, C., Milne-Price, S., Haddock, E., and Haagmans, B.L. (2013). The Middle East respiratory syndrome coronavirus (MERS-CoV) does not replicate in Syrian hamsters. PLoS ONE, 8.
Li, 2017, Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice, Proc. Natl. Acad. Sci. USA, 114, E3119
Zhao, G., Jiang, Y., Qiu, H., Gao, T., Zeng, Y., Guo, Y., Yu, H., Li, J., Kou, Z., and Du, L. (2015). Multi-Organ Damage in Human Dipeptidyl Peptidase 4 Transgenic Mice Infected with Middle East Respiratory Syndrome-Coronavirus. PLoS ONE, 10.
Zhao, 2014, Rapid generation of a mouse model for Middle East respiratory syndrome, Proc. Natl. Acad. Sci. USA, 111, 4970, 10.1073/pnas.1323279111
Tseng, 2007, Severe acute respiratory syndrome coronavirus infection of mice transgenic for the human Angiotensin-converting enzyme 2 virus receptor, J. Virol., 81, 1162, 10.1128/JVI.01702-06
Cockrell, 2016, A mouse model for MERS coronavirus-induced acute respiratory distress syndrome, Nat. Microbiol., 2, 16226, 10.1038/nmicrobiol.2016.226
Haagmans, 2016, An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels, Science, 351, 77, 10.1126/science.aad1283
Adney, 2016, Infection, Replication, and Transmission of Middle East Respiratory Syndrome Coronavirus in Alpacas, Emerg. Infect. Dis., 22, 1031, 10.3201/eid2206.160192
Crameri, 2016, Experimental Infection and Response to Rechallenge of Alpacas with Middle East Respiratory Syndrome Coronavirus, Emerg. Infect. Dis., 22, 1071, 10.3201/eid2206.160007
Yao, 2013, An Animal Model of MERS Produced by Infection of Rhesus Macaques with MERS Coronavirus, J. Infect. Dis., 209, 236, 10.1093/infdis/jit590
Yu, P., Xu, Y., Deng, W., Bao, L., Huang, L., Xu, Y., Yao, Y., and Qin, C. (2017). Comparative pathology of rhesus macaque and common marmoset animal models with Middle East respiratory syndrome coronavirus. PLoS ONE, 12.
Falzarano, D., de Wit, E., Feldmann, F., Rasmussen, A.L., Okumura, A., Peng, X., Thomas, M.J., van Doremalen, N., Haddock, E., and Nagy, L. (2014). Infection with MERS-CoV causes lethal pneumonia in the common marmoset. PLoS Pathog., 10.
Munster, 2013, Pneumonia from human coronavirus in a macaque model, N. Engl. J. Med., 368, 1560, 10.1056/NEJMc1215691
Falzarano, 2013, Treatment with interferon-alpha2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques, Nat. Med., 19, 1313, 10.1038/nm.3362
Johnson, 2015, Intratracheal exposure of common marmosets to MERS-CoV Jordan-n3/2012 or MERS-CoV EMC/2012 isolates does not result in lethal disease, Virology, 485, 422, 10.1016/j.virol.2015.07.013
Li, 2004, Efficient replication of severe acute respiratory syndrome coronavirus in mouse cells is limited by murine angiotensin-converting enzyme 2, J. Virol., 78, 11429, 10.1128/JVI.78.20.11429-11433.2004
Wu, 2005, Civets are equally susceptible to experimental infection by two different severe acute respiratory syndrome coronavirus isolates, J. Virol., 79, 2620, 10.1128/JVI.79.4.2620-2625.2005
Barlan, 2014, Receptor variation and susceptibility to Middle East respiratory syndrome coronavirus infection, J. Virol., 88, 4953, 10.1128/JVI.00161-14